期刊
PHARMACEUTICALS
卷 14, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/ph14090885
关键词
honokiol analogues; viral entry inhibitors; SARS-CoV-2; COVID-19; ACE2 blocker
资金
- Science and Technology Development Fund, Macau SAR [0065/2020/A2, 0074/2019/AMJ, 0043/2020/AGJ, 0064/2020/A]
- Emergency Key Program of Guangzhou Laboratory [EKPG21-06]
Novel honokiol analogues were synthesized and 6a and 6p showed promising antiviral entry effects with higher biological safety compared to the parental honokiol. These compounds may contribute to the discovery of potential viral entrance inhibitors for the SARS-CoV-2 virus.
The 2019 coronavirus disease (COVID-19) caused by SARS-CoV-2 virus infection has posed a serious danger to global health and the economy. However, SARS-CoV-2 medications that are specific and effective are still being developed. Honokiol is a bioactive component from Magnoliae officinalis Cortex with damp-drying effect. To develop new potent antiviral molecules, a series of novel honokiol analogues were synthesized by introducing various 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3H)-ones to its molecule. In a SARS-CoV-2 pseudovirus model, all honokiol derivatives were examined for their antiviral entry activities. As a result, 6a and 6p demonstrated antiviral entry effect with IC50 values of 29.23 and 9.82 mu M, respectively. However, the parental honokiol had a very weak antiviral activity with an IC50 value more than 50 mu M. A biolayer interfero-metry (BLI) binding assay and molecular docking study revealed that 6p binds to human ACE2 protein with higher binding affinity and lower binding energy than the parental honokiol. A competitive ELISA assay confirmed the inhibitory effect of 6p on SARS-CoV-2 spike RBD's binding with ACE2. Importantly, 6a and 6p (TC50 > 100 mu M) also had higher biological safety for host cells than honokiol (TC50 of 48.23 mu M). This research may contribute to the discovery of potential viral entrance inhibitors for the SARS-CoV-2 virus, although 6p's antiviral efficacy needs to be validated on SARS-CoV-2 viral strains in a biosafety level 3 facility.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据